Inactive Instrument

Press Releases Tobira Therapeutics Inc Nasdaq

Equities

US75874Q1076

Press Releases

Unlock all the news: Be the first to know and act before the market!

Tobira Therapeutics : Announces Late-Breaking Oral Presentation of CENTAUR Phase 2b Trial Results at the American Academy for the Study of Liver Diseases Annual Meeting	20/16/20	BU
Tobira Therapeutics : Announces Presentations Related to Cenicriviroc’s Development Program in NASH at the American Academy for the Study of Liver Diseases Annual Meeting	03/16/03	BU
TBRA Brower Piven Commences An Investigation Into The Proposed Sale Of Tobira Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information	22/16/22	BU
Tobira Therapeutics : Allergan to Acquire Tobira Therapeutics Expanding Global GI R&D Pipeline and Taking a Leading R&D Position in NASH	20/16/20	PU
Tobira Therapeutics : Announces Initiation of Phase 1 Combination Study of Cenicriviroc and Evogliptin	12/16/12	BU
Tobira Therapeutics : Announces Appointment of Dr. Laurent Fischer as Industry Co-chair of the Liver Forum Steering Committee	07/16/07	BU
Tobira Therapeutics : to Participate in Two Conferences in September	02/16/02	BU
Tobira Therapeutics : Reports Second Quarter 2016 Financial and Business Results	10/16/10	BU
Tobira Therapeutics : to Present at the 36th Annual Canaccord Genuity Growth Conference	02/16/02	BU
Tobira Therapeutics Announces Date of 2016 Second Quarter Financial Results and CENTAUR Study Update Conference Call	01/16/01	GL
Tobira Therapeutics : Announces Clinically and Statistically Significant Improvement in Liver Fibrosis From Phase 2b CENTAUR NASH Trial at One Year	25/16/25	BU
Tobira Therapeutics to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss CENTAUR Phase 2b Trial Results	25/16/25	BU
Tobira Therapeutics : Cenicriviroc Reduces Inflammation and Fibrosis in Animal Models of Chronic Liver and Kidney Disease Including NASH	28/16/28	PU
Tobira Therapeutics : Cenicriviroc Reduces Inflammation and Fibrosis in Animal Models of Chronic Liver and Kidney Disease Including NASH	28/16/28	BU
Tobira Therapeutics : Cenicriviroc Shown to Reduce Liver Injury in Independent Research Published in the Journal Hepatology	17/16/17	PU
Tobira Therapeutics : Cenicriviroc Shown to Reduce Liver Injury in Independent Research Published in the Journal Hepatology	17/16/17	BU
Tobira Therapeutics Announces Date of 2016 First Quarter Financial Results and Conference Call	02/16/02	GL
Tobira Therapeutics Announces Date of 2015 Fourth Quarter Financial Results and Conference Call	23/16/23	GL
Tobira Therapeutics : to Present at the Bank of America Merrill Lynch 2015 Health Care Conference	14/15/14	PU
Tobira Therapeutics : Completes Financing and Merger with Regado Biosciences	14/15/14	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Tobira Therapeutics Inc Nasdaq

Equities

US75874Q1076

Press Releases

Filters